FDA
-
-
-
-
-
-
-
Olema Pharmaceuticals (OLMA) Nominates OP-3136 as a Development Candidate
-
-
-
-
-
-
-
Olema Oncology Announces Expansion of Collaboration Agreement with Novartis
-
-
-
-
-
-
-
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
Olema Oncology Reports First Quarter 2023 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Olema Oncology to Present at Oppenheimer 33rd Annual Healthcare Conference
-
-
-
-
-
-
-
Olema Oncology Announces OP-1250 Demonstrates Attractive Combinability with CDK 4/6 Inhibitor Palbociclib in Phase 1b Dose Escalation Study
-
-
-
-
-
-
-
Olema Oncology Announces Complete ER Antagonist OP-1250 Continues to Demonstrate Robust Activity in Phase 1/2 Clinical Trial
-
322,084 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

